Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04685616 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Study acronym: RADAR
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 71 to 72v29
  2. Study sites: 70 to 71v28
  3. Study sites: 69 to 70v27
  4. Study sites: 65 to 69v26
  5. Study sites: 64 to 65v25
Show 23 earlier versionsHide 23 earlier versions
  1. Study sites: 62 to 64v24
  2. Study sites: 58 to 62v23
  3. Study sites: 57 to 58v22
  4. Study sites: 55 to 57v21
  5. Study sites: 50 to 55v20
  6. Study sites: 41 to 50v19
  7. Study sites: 38 to 41v18
  8. Study sites: 35 to 38v17
  9. Study sites: 27 to 35v16
  10. Study sites: 24 to 27v15
  11. Study sites: 21 to 24v14
  12. Study sites: 19 to 21v13
  13. Study sites: 17 to 19
    • Eligibility criteria expanded, about 8 words
    v12
  14. Study sites: 16 to 17v11
  15. Study sites: 15 to 16
    • Collaborators: 5 to 6
    v10
  16. Study sites: 11 to 15
    • Collaborators: 2 to 5
    v9
  17. Study sites: 9 to 11v8
  18. Study sites: 7 to 9v7
  19. Study sites: 6 to 7v6
  20. Study sites: 4 to 6v5
  21. Study sites: 3 to 4v4
  22. Trial status: Not Yet Recruiting to Recruitingv3 Show 5 more changesShow less
    • Start date changed from estimate of Nov 2021 to Apr 14, 2022
    • Study sites: 0 to 3
    • Primary completion date: Apr 2030 to Sep 2030
    • Study completion date: Apr 2032 to Sep 2032
    • Eligibility criteria expanded, about 19 words
  23. Start date: Jun 2021 to Nov 2021
    • Primary completion date: Dec 2029 to Apr 2030
    • Study completion date: Dec 2031 to Apr 2032
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry. Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy. An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation. Patients will be followed up for a minimum of 5 years after treatment.
Trial Details
NCT Number NCT04685616
Lead Sponsor University College, London
Collaborators: Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Conditions
(from sponsor)		 Hodgkin Lymphoma
Related terms Hodgkin Disease
Enrollment 1,042 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov